Clinical, epidemiological and therapeutic characteristics of Mycoplasma genitalium infection in a French STI center

Brin, C.; Palich, Romain; Godefroy, N.; Simon, Anne; Robert, Jérôme; Bebear, Cécile; Sougakoff, Wladimir; Agher, Rachid; Caumes, Éric; Monsel, Gentiane

doi:10.1016/j.idnow.2021.09.003

Cited by 2 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The database search yielded 1964 unique references. A total of 15 studies, reported in 17 publications, fulfilled the inclusion criteria and were included 32–48. The list of studies excluded after the full-text evaluation is presented in online supplemental material 3.…”

Section: Resultsmentioning

confidence: 99%

“…A total of 12 studies involving 2135 individuals were included in the meta-analysis of the point prevalence of MG in PrEP users 32–38 41–44 47. The pooled point prevalence of MG infection among the PrEP users was estimated at 16.7% (95% CI 13.6% to 20.3%), as presented in figure 2.…”

Section: Resultsmentioning

confidence: 99%

“…For this reason, further prevalence studies are required to address these limitations. Moreover, 2 studies tested only urine samples,43 46 and 11 studies tested urine and anorectal samples to diagnose MG 32 34 36–41 44 45 47. However, anorectal swabs are especially relevant for MSM, and not testing this site may result in an underestimation of MG prevalence by up to 70% 44 58.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence ofMycoplasma genitaliuminfection among HIV PrEP users: a systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

ObjectivesTo summarise the prevalence ofMycoplasma genitalium(MG) and antibiotic-resistant MG infection among HIV pre-exposure prophylaxis (PrEP) users.MethodsWe searched MEDLINE, Embase, Web of Science and Global Index Medicus up to 30 September 2022. We included studies reporting the prevalence of MG and/or antibiotic-resistant MG infection among PrEP users. Two reviewers independently searched for studies and extracted data. A systematic review with random-effects meta-analysis was performed to quantitatively summarise the results of included studies. The critical appraisal of included studies was conducted with the Joanna Briggs Institute checklist for prevalence studies and the quality of evidence was assessed with Grading of Recommendations Assessment, Development and Evaluation (GRADE).ResultsA total of 15 studies were included in the systematic review, with 2341 individuals taking PrEP. Studies were conducted in high-income level countries between 2014 and 2019. Median age of participants varied from 23.5 to 40 years. The majority were men (85%) and among them, 93% were men who have sex with men. To identify MG, urine samples were analysed in 14 studies, rectal or anal swabs in 12 studies, oral or pharyngeal swabs in 9 studies, and urethral or vaginal in 3 studies. The pooled point prevalence of MG among PrEP users was 16.7% (95% CI 13.6% to 20.3%; 95% prediction interval (95% PI) 8.2% to 31.1%). The pooled point prevalence of macrolide-resistant infections was 82.6% (95% CI 70.1% to 90.6%; 95% PI 4.7% to 99.8%) and the prevalence of fluoroquinolone-resistant infections was 14.3% (95% CI 1.8% to 42.8%). Individuals taking PrEP have a higher chance of being infected with MG compared with those not taking PrEP (OR 2.30; 95% CI 1.6 to 3.4). The quality of evidence was very low to moderate.ConclusionWe observed a high prevalence of MG and its macrolide resistance among PrEP users, highlighting the need to reinforce prevention strategies against sexually transmitted infections in this population.PROSPERO registration numberCRD42022310597.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%